List of Excipients in Branded Drug TELMISARTAN

Generic Drugs Containing TELMISARTAN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	telmisartan	0378-2920	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	telmisartan	0378-2920	MANNITOL
Mylan Pharmaceuticals Inc	telmisartan	0378-2920	MEGLUMINE
Mylan Pharmaceuticals Inc	telmisartan	0378-2920	POVIDONE
Mylan Pharmaceuticals Inc	telmisartan	0378-2920	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TELMISARTAN?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
18	CROSPOVIDONE
4	FERRIC OXIDE RED
12	LACTOSE MONOHYDRATE

Telmisartan Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Telmisartan is an established, orally administered angiotensin II receptor blocker with generic status in major markets. Its commercial opportunity is no longer based on the active ingredient patent. It depends on formulation performance, fixed-dose combinations, manufacturing efficiency, patient-centric dosage forms, and differentiated regulatory pathways.

The central formulation problem is poor aqueous solubility. Telmisartan is practically insoluble in water and has pH-dependent dissolution behavior. The branded Micardis formulation uses an alkaline microenvironment and solubilizing excipients, including meglumine and sodium hydroxide, to improve dissolution and oral exposure [1]. This creates opportunities for lower-cost generic tablets, orally disintegrating tablets, pediatric formulations, combination products, and advanced solubility-enhanced products.

What excipients are used in branded telmisartan tablets?

The original Micardis formulation uses excipients that support alkalinity, wetting, granulation, tablet manufacture, and stability.

Function	Branded excipient or excipient class	Formulation role
pH modifier and solubilizer	Meglumine	Creates an alkaline microenvironment and improves apparent solubility
Alkalizing agent	Sodium hydroxide	Raises microenvironmental pH
Binder and solubilizer	Povidone	Supports granulation and drug dispersion
Filler and processing aid	Sorbitol	Contributes to tablet mass and mouthfeel
Lubricant	Magnesium stearate	Supports compression and tablet ejection
Additional excipients in combination products	Lactose, starches, pigments and related materials	Support dose loading, appearance and manufacturability

The Micardis label identifies meglumine, sodium hydroxide, povidone, sorbitol and magnesium stearate among the inactive ingredients for telmisartan tablets [1]. The formulation is commercially important because it demonstrates that telmisartan performance can be improved without relying only on conventional surfactants or a complex delivery system.

Why does telmisartan require a specialized excipient strategy?

Telmisartan has low water solubility, while its permeability is adequate for oral absorption. The principal formulation risk is therefore dissolution and dispersion rather than membrane transport.

Three variables control product performance:

1. Microenvironmental pH within the tablet and gastrointestinal tract.
2. Drug particle size, crystallinity and wetting.
3. Maintenance of rapid dissolution after storage.

A formulation with excessive alkalinity may improve dissolution but create stability, compatibility, taste, or manufacturing problems. A formulation with insufficient alkalinity may fail dissolution testing even when the drug substance has acceptable particle size.

The most practical strategy is to establish a controlled alkaline microenvironment using a combination of meglumine and an inorganic base, then optimize binder level, disintegrant selection, compression force and granule porosity.

What excipient combinations are most commercially attractive?

Meglumine-based alkaline systems

Meglumine is the closest platform to the branded product. It can improve telmisartan solubility and supports a relatively conventional immediate-release tablet.

Commercial advantages include:

• A well-established formulation concept.
• Compatibility with standard wet granulation.
• Potentially strong dissolution performance.
• Straightforward positioning for generic development.

Development risks include hygroscopicity, tablet hardness changes, and potential sensitivity to granulation water or drying conditions. Meglumine level must be optimized because excess excipient can increase tablet size and manufacturing cost.

Sodium hydroxide or carbonate systems

Sodium hydroxide, sodium carbonate and related alkaline agents can increase local pH. These systems may reduce the amount of organic solubilizer required.

The main risks are formulation heterogeneity and local pH excursions during manufacture. Excess inorganic base may affect stability, taste, tablet surface characteristics and compatibility with other active ingredients.

Surfactant-assisted systems

Poloxamers, sodium lauryl sulfate and related surfactants can improve wetting and dissolution. They may be useful when a developer is seeking to reduce the meglumine load or develop a smaller tablet.

Surfactants require careful control of:

• Foaming during granulation.
• Lubrication and compression behavior.
• Oxidative and chemical compatibility.
• Dissolution robustness across pH conditions.

Solid-dispersion and amorphous systems

Hot-melt extrusion, spray drying and polymeric solid dispersions can increase apparent solubility. Suitable polymers may include povidone, copovidone, hydroxypropyl cellulose and hypromellose derivatives.

These systems have greater differentiation potential than conventional tablets but also higher process and scale-up risk. Amorphous telmisartan must be monitored for recrystallization, particularly under elevated humidity and temperature.

Cyclodextrin and lipid-based systems

Cyclodextrins, self-emulsifying systems and lipid formulations can improve apparent solubility. Their use is more likely to support a 505(b)(2) product, specialty formulation or new dosage form than a low-cost ANDA.

The commercial case depends on whether the formulation delivers a measurable benefit, such as faster onset, reduced food effect, improved dose flexibility or use in patients unable to swallow tablets.

What dosage forms offer the strongest commercial opportunity?

Immediate-release generic tablets

Immediate-release tablets remain the largest and lowest-risk opportunity. The principal competitive levers are:

• Cost of goods.
• Dissolution robustness.
• Tablet size.
• Stability in tropical climates.
• Packaging and moisture protection.
• Reliable supply of active pharmaceutical ingredient and excipients.

A developer can compete without copying the branded excipient composition, provided the formulation meets applicable sameness, quality and bioequivalence requirements.

Fixed-dose combinations

Telmisartan is commercially suited to fixed-dose combinations because hypertension and cardiovascular-risk patients often require multiple agents. Existing combinations include telmisartan with hydrochlorothiazide and amlodipine. The U.S. labels for Micardis HCT and Twynsta identify these products and their approved strengths [2,3].

Potential combination categories include:

Combination	Commercial rationale
Telmisartan/hydrochlorothiazide	Broad hypertension use and established market
Telmisartan/amlodipine	Single-pill therapy for patients requiring dual antihypertensive treatment
Telmisartan/other antihypertensive agents	Potential adherence and dose-titration benefits
Telmisartan/metabolic or cardiovascular agents	Requires stronger clinical and regulatory differentiation

Combination products create formulation challenges because the second active ingredient may not tolerate the same alkaline environment. Hydrochlorothiazide, amlodipine and telmisartan have different solubility, stability and compression requirements. Bilayer tablets, separate granulation phases and protective coatings can reduce incompatibility.

Orally disintegrating tablets

An orally disintegrating tablet could target older patients, dysphagia, polypharmacy and patients with poor adherence. The main technical challenge is balancing rapid disintegration with the alkaline excipient system.

Potential excipients include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, mannitol and taste-masking agents. Sorbitol may support mouthfeel but can introduce hygroscopicity and gastrointestinal tolerability concerns at higher loads.

Pediatric and geriatric liquid formulations

Telmisartan oral suspensions or dispersible products could support pediatric hypertension, dose flexibility and patients unable to swallow tablets. These products carry greater stability and preservative-development burdens.

An alkaline liquid may improve solubility but can create taste, compatibility and shelf-life issues. A suspension approach may be more practical if the product can maintain uniform dosing and acceptable redispersibility.

Modified-release products

Modified release is a higher-risk opportunity. Telmisartan is generally used as an immediate-release product, and the commercial benefit of extending release is not automatically clear. A modified-release product would need to demonstrate a clinically relevant advantage, such as improved tolerability, adherence or blood-pressure control.

How strong is the patent estate for telmisartan formulations?

The original telmisartan compound patent estate has expired in the United States. Telmisartan was approved by the FDA in 1998 under NDA 020850 for Micardis [1]. The principal U.S. composition-of-matter patent, U.S. Patent No. 5,591,762, had an expiration date in the early 2010s after applicable term calculations and extensions. Generic telmisartan products are therefore widely marketed.

IP category	Commercial status
Telmisartan compound patent	Expired in major generic markets
Original immediate-release product protection	Expired or no longer a material barrier to ordinary generic entry
Combination-product patents	Largely expired for established products, subject to jurisdiction and claim scope
Later formulation patents	May remain relevant for specific dosage forms, processes or compositions
Manufacturing patents	Can create narrower barriers if claims cover scalable processes or crystalline forms
Trademark rights	Remain distinct from active-ingredient patent rights

A formulation patent does not automatically block ordinary telmisartan tablets. Its value depends on claim breadth, validity, enforceability, regulatory relevance and whether a competing product must practice the claimed excipient system.

What is the Orange Book status of telmisartan?

The FDA Orange Book identifies approved drug products, patent listings and exclusivity information. Telmisartan reference products include Micardis and combination products such as Micardis HCT and Twynsta, subject to the FDA’s current listing status [4].

For generic developers, the key Orange Book questions are:

• Whether the reference product has listed patents.
• Whether a listed patent covers the active ingredient, formulation, method of use or product-specific feature.
• Whether the relevant patent has expired.
• Whether the ANDA requires a Paragraph IV certification.
• Whether pediatric exclusivity or other regulatory exclusivity remains active.

For legacy telmisartan tablets, ordinary generic entry is generally a mature-market issue rather than a current compound-patent challenge. Product-specific patents may still matter for particular combinations or delivery systems, but they should be assessed separately from the expired telmisartan molecule patent.

When did telmisartan lose exclusivity?

Telmisartan lost effective U.S. compound exclusivity in the early 2010s. FDA-approved generic telmisartan products entered the U.S. market after the relevant exclusivity and patent barriers ended.

The practical timeline is:

Milestone	Timing
U.S. approval of Micardis	1998
U.S. approval of Micardis HCT	2000
U.S. approval of Twynsta	2009
Compound-patent protection	Ended in the early 2010s
Generic competition	Established in the U.S. and other major markets
Current opportunity	Formulation, combination, geographic and supply-chain competition

Exact launch dates and listed patent positions must be checked by product and jurisdiction because telmisartan, hydrochlorothiazide and amlodipine combinations have separate regulatory histories.

Which companies compete in telmisartan?

Competition is fragmented across multinational and regional generic manufacturers. Teva, Mylan/Viatris, Apotex, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Lupin, Zydus, Sun Pharma, Cipla and numerous regional manufacturers have marketed telmisartan or telmisartan combinations in different markets, subject to local approvals.

The strongest competitive positions usually come from:

• Integrated API and finished-dose manufacturing.
• Low-cost high-volume tablet production.
• Established government-tender access.
• Broad combination portfolios.
• Local regulatory registrations.
• Reliable supply during price pressure.

The active ingredient is widely available, reducing the value of a simple “me-too” tablet. A new entrant needs either a cost advantage, a distribution advantage, a differentiated combination or a dosage-form benefit.

What generic launch risks exist for telmisartan?

Regulatory risk

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. Excipients may differ, but differences cannot compromise product quality, dissolution, stability or safety.

Combination products may require more complex bioequivalence strategies because each active ingredient must meet applicable criteria.

Formulation risk

The main risks are:

• Failure to reproduce dissolution across pH conditions.
• Precipitation after initial solubilization.
• Moisture-driven potency or dissolution changes.
• Incompatibility between alkaline excipients and the second active ingredient.
• Excessive tablet size caused by solubilizer loading.
• Manufacturing variability from nonuniform pH distribution.

Patent and litigation risk

Paragraph IV risk is highest where a sponsor targets a product with unexpired listed patents. For mature telmisartan tablets, the risk is lower than for newer branded products, but combination and formulation patents require product-specific review.

Commercial risk

Prices are compressed in mature antihypertensive markets. A launch based only on a standard tablet may produce limited returns unless the applicant has efficient manufacturing, market access or a differentiated supply proposition.

How do telmisartan excipient opportunities compare with other ARBs?

Drug	Solubility and formulation profile	Excipient opportunity
Telmisartan	Poor aqueous solubility; alkaline formulation strategy is important	High opportunity for pH-modified, dispersible and combination products
Valsartan	Solubility and dissolution challenges; extensive combination use	Strong combination and formulation opportunity, with additional supply-chain scrutiny
Losartan	More conventional generic platform	Lower formulation differentiation, stronger cost competition
Irbesartan	Poorly soluble, immediate-release products common	Similar solubility-enhancement opportunity
Candesartan cilexetil	Prodrug with dissolution and conversion considerations	Higher formulation complexity and potential differentiation
Olmesartan medoxomil	Prodrug with established combination products	Combination and patient-centric dosage forms remain relevant

Telmisartan is attractive for excipient innovation because its low solubility creates a real formulation problem, but the molecule’s age limits the price premium available for ordinary improvements.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers are more important than basic compound patents. A commercially credible formulation should control:

• API particle-size distribution.
• Specific surface area and polymorphic form.
• Alkaline excipient uniformity.
• Granulation endpoint.
• Residual moisture.
• Compression force.
• Dissolution after accelerated stability.
• Packaging performance in high humidity.

Potential IP protection may focus on a defined excipient ratio, pH range, particle-size distribution, solid-state form, process sequence or combination architecture. Broad claims covering “telmisartan plus a solubilizer” are more vulnerable where the concept is disclosed in the branded product or earlier prior art.

What licensing deals and partnership models are available?

Telmisartan licensing is more likely to involve regional distribution, combination products, API supply or contract manufacturing than exclusive molecule licensing.

Commercial partnership models include:

1. Regional licensing of approved telmisartan combinations.
2. API and finished-dose supply agreements.
3. Co-development of orally disintegrating or dispersible formulations.
4. Contract manufacturing for government tenders.
5. Technology transfer for local production.
6. Licensing of formulation patents in markets where protection remains active.

The most defensible partnership opportunity is a product with a measurable regulatory or commercial distinction, such as a stable low-dose formulation, a combination tablet with a smaller pill burden, or a dispersible dosage form for patients with swallowing difficulty.

Key Takeaways

• Telmisartan is a mature generic active ingredient with expired core compound protection in major markets.
• The main formulation challenge is poor aqueous solubility and pH-dependent dissolution.
• Meglumine, sodium hydroxide and povidone provide the established excipient framework.
• The strongest near-term opportunities are fixed-dose combinations, orally disintegrating tablets, dispersible products and manufacturing-cost improvements.
• Formulation patents may remain relevant, but their value depends on claim breadth and jurisdiction.
• API quality, pH uniformity, moisture control and dissolution robustness are central manufacturing barriers.
• A conventional telmisartan tablet is a low-margin opportunity unless supported by scale, distribution or supply-chain advantages.
• Licensing value is more likely in combinations, regional commercialization and formulation technology than in the molecule itself.

FAQs

Can telmisartan be formulated without meglumine?

Yes. Alternative systems can use inorganic bases, carbonate buffers, surfactants, solid dispersions or particle-engineering approaches. The replacement must deliver adequate dissolution, stability and bioequivalence.

Is telmisartan suitable for an orally disintegrating tablet?

Yes, but the alkaline solubilization system must be balanced against taste, hygroscopicity, tablet size and mechanical strength. Mannitol, crospovidone and taste-masking technologies may support development.

Are telmisartan combination tablets more valuable than single-ingredient tablets?

Usually. Combination tablets reduce pill burden and support commercial differentiation, but they require separate control of active-ingredient compatibility, dose proportionality, dissolution and bioequivalence.

Does a telmisartan formulation patent block all generic tablets?

No. A formulation patent normally covers only the claimed composition, process, dosage form or use. A generic can avoid infringement through a non-infringing formulation, subject to applicable regulatory and patent requirements.

What is the best commercial excipient strategy for telmisartan?

For a standard generic, a controlled alkaline immediate-release tablet using a low-cost, robust solubilization system is the most practical strategy. For differentiation, an orally disintegrating, dispersible or fixed-dose combination product offers greater commercial potential.

References

1. U.S. Food and Drug Administration. (1998). Micardis (telmisartan) prescribing information.
2. U.S. Food and Drug Administration. (2000). Micardis HCT (telmisartan and hydrochlorothiazide) prescribing information.
3. U.S. Food and Drug Administration. (2009). Twynsta (telmisartan and amlodipine) prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book.
5. U.S. Patent No. 5,591,762. (1997). Benzimidazole derivatives as angiotensin II antagonists.
6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
7. World Health Organization. (2006). WHO monographs on selected medicinal plants and pharmaceutical substances.